MODERNA INC (1MRNA.MI) Stock Price, Forecast & Analysis
BIT:1MRNA • US60770K1079
1MRNA.MI Key Statistics, Chart & Performance
The current stock price of 1MRNA.MI is 39.34 EUR. In the past month the price increased by 20.9%. In the past year, price decreased by -2.41%.
1MRNA.MI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 1MRNA.MI. When comparing the yearly performance of all stocks, 1MRNA.MI is one of the better performing stocks in the market, outperforming 83.09% of all stocks.
1MRNA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI. While 1MRNA.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
1MRNA.MI Financial Highlights
Over the last trailing twelve months 1MRNA.MI reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS increased by 21.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| Debt/Equity | 0 |
1MRNA.MI Forecast & Estimates
30 analysts have analysed 1MRNA.MI and the average price target is 34.33 EUR. This implies a price decrease of -12.75% is expected in the next year compared to the current price of 39.34.
For the next year, analysts expect an EPS growth of 2.17% and a revenue growth 6.38% for 1MRNA.MI
1MRNA.MI Ownership
1MRNA.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.32 | 44.408B | ||
| 1AE | ARGENX SE | 28.26 | 44.383B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.99B | ||
| 2X1 | ABIVAX SA | N/A | 8.714B | ||
| ABVX | ABIVAX SA | N/A | 8.698B | ||
| GLPG | GALAPAGOS NV | N/A | 1.902B | ||
| GXE | GALAPAGOS NV | N/A | 1.897B | ||
| IVA | INVENTIVA SA | N/A | 1.153B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.079B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1MRNA.MI
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 5800
Phone: 16177146500
MODERNA INC / 1MRNA.MI FAQ
Can you describe the business of MODERNA INC?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the current price of 1MRNA stock?
The current stock price of 1MRNA.MI is 39.34 EUR. The price increased by 10.27% in the last trading session.
What is the dividend status of MODERNA INC?
1MRNA.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MRNA stock?
1MRNA.MI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is MODERNA INC (1MRNA.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1MRNA.MI.
How many employees does MODERNA INC have?
MODERNA INC (1MRNA.MI) currently has 5800 employees.